Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 3, 2005, Pages 99-115

  Bae, Soo K ^a   Lee, Shin J ^a   Kim, Yoon G ^b   Kim, So H ^c   Kim, Jin W ^d   Kim, Taekrho ^d   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dankook University   (South Korea)

^c Gangneung Wonju National University   (South Korea)

^d CJ Corporation   (South Korea)

Author keywords

Animal scale up; Dienetichron; Dogs; Mice; Oltipraz; Pharmacokinetics; Rabbits; Rats

Indexed keywords

6 (1 HYDROXYETHYL) 2 [2 (3 METHANESULFONYLAMINO 1 PROPENYL) 4 PYRROLIDINYLTHIO] 1 METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CARBAPENEM; LAMIFIBAN; OLTIPRAZ; PANIPENEM PLUS BETAMIPRON; SJ 8029; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; MALE; MOUSE; NONHUMAN; PREDICTION; RABBIT; RAT; SPECIES COMPARISON; STEADY STATE;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; DOGS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICE; PREDICTIVE VALUE OF TESTS; PYRAZINES; RABBITS; RATS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 17844409345     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.437     Document Type: Article

References (45)

1. Clapper M. Chemopreventive activity of oltipraz. Pharmacol Ther 1998; 78: 17-27.
2. Bueding E, Dolan P, Leroy JP. The antischistosomal activity of oltipraz. Res Commun Mol Pathol Pharmacol 1982; 37: 293-303.
3. Primiano T, Egner PA, Sutter TR, Kellof GJ, Roebuds BD, Kensler TW. Intermittent dosing with oltipraz: Relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione-S-transferases. Cancer Res 1995; 55: 4319-4324.
4. Kang KW, Kim WG, Cho MK, et al. Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation, FASEB J 2002; 16: 1988-1990.
5. Bae SK, Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. Determination of a chemopreventive agent, oltipraz, in rat plasma and urine by high-performance liquid chromatography. Res Commun Mol Pathol Pharmacol 2001; 110: 133-138.
6. Bu SC, Kim EJ, Kim SH, Kim SG, Lee MG. Stability, blood partition and protein binding of an antifibrotic agent, oltipraz. Res Commun Mol Pathol Pharmacol 2001; 109: 333-344.
7. Bae SK, Kim EJ, Chung SJ, Kim SG, Lee MG. Pharmacokinetic interaction between oltipraz and dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylenedioxybiphenyl-2, 2′-dicarboxylate (DDB) after single intravenous and oral administration to rats. J Pharm Pharmacol 2003; 55: 1241-1249.
8. Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours. Biopharm Drug Dispos 2004; 26: 77-83.
9. Bae SK, Lee SJ, Kim JW, Kim YH, Kim SG, Lee MG. Effects of acute renal failure on the pharmacokinetics of oltipraz in rats. J Pharm Sci 2004; 93: 2353-2363.
10. Bae SK, Lee SJ, Lee JY, et al. Pharmacokinetics changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int J Pharm 2004; 275 227-238.
11. Bae SK, Yang SH, Kim JW, Kim T, Kwon JW, Lee MG. Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition. J Pharm Sci (revised manuscript submitted).
12. Bae SK, Lee SJ, Kim YH, Kim T, Lee MG. Effects of enzyme inducers or inhibitors on the pharmacokinetics of intravenous oltipraz in rats. J Pharm Pharmacol (in press).
13. Adolph EF. Quantitative relations in the physiological constitutions of mammals. Science 1949; 109: 579-585.
14. Kurihara A, Naganuma H, Hisaoka M, Yokiwa H, Kawahara Y. Prediction of human pharmacokinetics of panipenem - betamipron, a new carbapenem, from animal data. Antimicrob Agents Chemother 1992; 36: 1810-1816.
15. Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 1998; 19: 231-235.
16. Shin BS, Kim DH, Cho CY, et al. Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. Biopharm Drug Dispos 2003; 24: 191-197.
17. Lave T, Saner A, Coassolo P, Brandt R, Schmitt-Hoffmann AH, Chou RC. Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor. J Pharm Pharmacol 1996; 48: 573-577.
18. Hutchaleelaha A, Chow H-H, Mayersohn M. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 1997; 49: 178-183.
19. Yoon WH, Yoo JK, Lee JW, Shim C-K, Lee MG. Species differences in pharmacokinetics of a hepatoprotective agent, YH439, and its metabolites, M4, M5, and M7, after intravenous and oral administration to rats, rabbits, and dogs. Drug Metab Dispos 1998; 26: 152-163.
20. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 1993; 21: 1-17.
21. Chang HW, Lee MG, Lee H, Park MK, Kim C-K. Effects of leucovorin on the pharmacokinetics of methotrexate in rabbits. Int J Pharm 1992; 79: 71-75.
22. Chiou WL, Riegelman S, Amberg JR. Complication in using rabbits for the study of oral drug absorption. Chem Pharm Bull 1969; 17: 2170-2173.
23. Lui CY, Lee MG, Chiou WL. Concentration and pH dependent steady-state volume of distribution of metho-trexate estimated by simple physiologically based method. J Pharmacokinet Biopharm 1984; 12 597-610.
24. Christensen RG, Malone W. Determination of oltipraz in serum by high-performance liquid chromatography with optical absorbance and mass spectrometric detection. J Chromatogr 1992; 584: 207-212.
25. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker: New York, 1982.
26. Chiou WL. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 1979; 68: 1067-1069.
27. Eatman FB, Colburn WA, Boxenbaum. HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 1977; 5: 481-494.
28. Chiou WL. New calculation method of mean total body clearance of drugs and its application to rational dosage regimens. J Pharm Sci 1980; 69: 90-91.
29. Boxenbaum H. Interspecies scaling, allometry physiological time and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201-227.
30. Sacher GA. Relationship of life-span to brain weight and body weight in mammals. CIBA Found Coll Ageing 1959; 5: 115-133.
31. Kessler FK, Ritter JK. Induction of a rat liver benzo[a]pyrene-trans-7,8-dihydrodiol glucuronidating activity by oltipraz and beta-naphthoflavone. Carcinogenesis 1998; 18: 107-114
32. 14C-oltipraz in animals. Pharmacokinetics in mice, rats and monkeys. Comparison of the biotransformation in the infected mouse and in the schistosomes. Arzneimittel Forsch/Drug Res 1985; 35: 1431-1436.
33. Maheo K, Morel F, Antras-Ferry J, et al. Endotoxin suppresses the oltipraz-mediated induction of major hepatic glutathione transferases and cytochromes P450 in the rat. Hepatology 1998; 28: 1655-1662.
34. Davis B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095.
35. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. Comparison of gastrointestinal pH in dogs and humans: Implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 1986; 75: 271-274.
36. Bae SK, Kim YG, Kim JW, Kim YH, Kim SG, Lee MG. Hepatic and intestinal first-pass effects of oltipraz in rats. Biopharm Drug Dispos (in press).
37. Bieder A, Decouvelaere B, Gaillard C, et al. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneimittel Forsch/Drug Res 1983; 33: 1289-1297.
38. Mitruka BM, Rawnsley HM. Clinical Biochemical and Hematological Reference Values in Normal Humans, 2nd edn. Masson: New York, 1981.
39. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric firstpass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640.
40. Dedrick RL. Animal scale-up. J Pharmacokinet Bioharm 1973; 1: 435-461.
41. Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res 1990; 50: 2692-2697.
42. Dedrick RL, Bischoff KB, Zaharko DS. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970; 54: 95-101.
43. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8: 1351-1359.
44. Mordenti J. Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 1991; 75: 1028-1040.
45. Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245: R768-R775.